Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Xilio Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 37
- +2 vs. Q3 2025
- Shares held
- 39.7M
- +19.2M (+93.1%) vs. Q3 2025
- Total value
- $25.4M
- +$8.06M (+46.4%) vs. Q3 2025
- New holders
- 11
- 5 more added
- Sold out
- 9
- 5 more reduced
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 203 | $130 | 0.00% | −13,449−98.5% | Reduced |
| Bank of America Corp | 261 | $167 | 0.00% | +15+6.1% | Added |
| Private Wealth Management Group, LLC | 310 | $199 | 0.00% | 00.0% | Unchanged |
| Key Financial Inc | 830 | $531 | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 2,037 | $1.30K | 0.00% | 00.0% | Unchanged |
| Investors Asset Management of Georgia Inc | 10,000 | $6.40K | 0.00% | 00.0% | Unchanged |
| Pinnacle Financial Group, LLC | 10,000 | $6.40K | 0.00% | 00.0% | Unchanged |
| Dunhill Financial, LLC | 10,274 | $6.58K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 17,304 | $11.1K | 0.00% | −58,741−77.2% | Reduced |
| Raymond James Financial Inc | 18,761 | $12.0K | 0.00% | 00.0% | Unchanged |
| LPL Financial LLC | 21,000 | $13.4K | 0.00% | −10,000−32.3% | Reduced |
| Mariner, LLC | 25,000 | $16.0K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 31,886 | $20.0K | 0.00% | +7,150+28.9% | Added |
| Jane Street Group, LLC | 42,080 | $26.9K | 0.00% | +42,080 | New |
| Bridgeway Capital Management, LLC | 56,081 | $35.9K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 62,032 | $39.7K | 0.00% | −25,758−29.3% | Reduced |
| Northern Trust Corp | 66,609 | $42.6K | 0.00% | 00.0% | Unchanged |
| Stonepine Capital Management, LLC | 126,270 | $80.8K | 0.06% | +126,270 | New |
| Gsa Capital Partners LLP | 147,966 | $95.0K | 0.01% | +147,966 | New |
| Velan Capital Investment Management LP | 170,000 | $108.8K | 0.06% | +170,000 | New |
| State Street Corp | 186,390 | $119.3K | 0.00% | +22,500+13.7% | Added |
| Geode Capital Management, LLC | 328,972 | $210.6K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 344,416 | $220.5K | 0.00% | +139,716+68.3% | Added |
| Citadel Advisors LLC | 436,216 | $279.3K | 0.00% | +436,216 | New |
| FMR LLC | 511,820 | $327.7K | 0.00% | 00.0% | Unchanged |
| AJU IB Investment Co., Ltd. | 667,742 | $427.5K | 2.29% | 00.0% | Unchanged |
| Morgan Stanley | 839,850 | $537.7K | 0.00% | −122,067−12.7% | Reduced |
| Ghisallo Capital Management LLC | 1,113,222 | $712.7K | 0.03% | +1,113,222 | New |
| Empery Asset Management, LP | 1,183,040 | $757.4K | 0.67% | +1,183,040 | New |
| Vanguard Group Inc | 1,255,692 | $803.6K | 0.00% | 00.0% | Unchanged |
| Merck & Co., Inc. | 1,483,758 | $949.9K | 0.34% | 00.0% | Unchanged |
| StemPoint Capital LP | 2,030,028 | $1.30M | 0.22% | +2,030,028 | New |
| Sio Capital Management, LLC | 2,134,537 | $1.37M | 0.23% | +2,134,537 | New |
| Point72 Asset Management, L.P. | 4,000,000 | $2.56M | 0.00% | +4,000,000 | New |
| Frazier Life Sciences Management, L.P. | 5,915,091 | $3.79M | 0.10% | +5,915,091 | New |
| Bain Capital Life Sciences Investors, LLC | 7,372,686 | $4.72M | 0.36% | +2,805,869+61.4% | Added |
| Gilead Sciences, Inc. | 9,105,451 | $5.83M | 0.30% | 00.0% | Unchanged |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −328,794−100.0% | Sold out |
| Trustees of Columbia University in the City of New York | 0 | $0 | 0.00% | −249,635−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −198,859−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −32,130−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −29,689−100.0% | Sold out |
| Aptus Capital Advisors, LLC | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| SevenBridge Financial Group, LLC | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Federation des caisses Desjardins du Quebec | 0 | $0 | 0.00% | −3,300−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −258−100.0% | Sold out |
| Takeda Pharmaceutical Co Ltd | – | – | – | – | Not filed |